Roivant Sciences Ltd. (ROIV): David Einhorn Trims Stake [Yahoo! Finance]
Roivant Sciences Ltd. - Common Shares (ROIV)
Company Research
Source: Yahoo! Finance
Roivant Sciences Ltd. (NASDAQ:ROIV) has been a consistent feature in the 13F portfolio of Greenlight Capital since the first quarter of 2024. Back then, this position comprised 4.1 million shares. By the third quarter of 2024, the fund had grown this holding to 5.3 million shares. After the first quarter of 2025, the fund started trimming this stake. Filings for the fourth quarter of 2025 show that the fund owned a little over 2 million shares in the firm, down close to 10% compared to filings for the third quarter of 2025. Roivant is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of medicines. How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform Roivant Sciences Ltd. (NASDAQ:ROIV) recently announced a $2.25 billion global settlement with Moderna regarding COVID-19 vaccine patents. This non-dilutive capital injection has significantly bolstered the balance sheet of the firm. Beyond the lead candidat
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant Sciences: Moderna Settlement And Brepocitinib Support A Long-Term Buy [Seeking Alpha]Seeking Alpha
- Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences (ROIV) was given a new $40.00 price target by Piper Sandler.MarketBeat
- Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure [Yahoo! Finance]Yahoo! Finance
- Ohio governor: Vivek Ramaswamy faces little-known GOP challengers [USA TODAY]USA TODAY
ROIV
Earnings
- 2/6/26 - In-Line
ROIV
Sec Filings
- 4/22/26 - Form 4
- 4/22/26 - Form 4
- 4/22/26 - Form 4
- ROIV's page on the SEC website